Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the management of patients with AML.
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
In a presentation at the 2024 International Pathology Day virtual conference, Dr Justin Loke, CRUK/AACR Transatlantic Fellow, University of Birmingham, UK and Dana-Farber Cancer Institute, USA, explains how…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors…
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Fatima Tuz Zahra, MD, a hematology/oncology fellow at Moffitt Cancer Center, University of South Florida, Tampa, presented real-world data from a retrospective study evaluating the effectiveness of oral…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
